An Immuno-Infrared Sensor Detects Preclinical Alzheimer’s and Parkinson’s Disease by Protein Misfolding
Open Access
- 24 April 2026
- journal article
- review article
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry B
- Vol. 130 (18) , 4711-4719
Abstract
The immuno-infrared sensor (iRS) detects misfolding of biomarker proteins in blood and provides thereby a very early and easily accessible diagnosis of Alzheimer’s and Parkinson’s disease. Only in early stages recently approved therapeutic Alzheimer′s drugs work efficiently. In symptom-free stages, lifestyle change can largely delay the disease progression, and the drugs may even block the disease progression. Population screening by a simple blood test will therefore be a game changer in the fight against neurodegenerative diseases. This was made possible by the new iRS platform. In the iRS platform, antibodies as catcher molecules concentrate the target protein biomarker on the functionalized attenuated total reflection crystal surface. A blocking layer prevents unspecific binding. A quantum cascade laser is used to measure the amide I absorbance maximum as a readout, indicating the degree of the biomarker misfolding and thereby disease progression.Keywords
Funding Information
- Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen
This publication has 33 references indexed in Scilit:
- Alzheimer's disease drug development pipeline: 2025Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2025
- α‐Synuclein Seed Amplification Assays from Blood‐Based Extracellular Vesicles in Parkinson's Disease: An Evaluation of the EvidenceMovement Disorders, 2024
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease PathologyJAMA Neurology, 2024
- Accurate Detection of α‐Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) CohortMovement Disorders, 2023
- Amyloid‐beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 yearsAlzheimer's & Dementia, 2022
- TDP‐43 as structure‐based biomarker in amyotrophic lateral sclerosisAnnals of Clinical and Translational Neurology, 2020
- Quantum cascade laser-based infrared transmission spectroscopy of proteins in solution2020
- Ligand‐Induced Conformational Changes in HSP90 Monitored Time Resolved and Label Free—Towards a Conformational Activity Screening for Drug DiscoveryAngewandte Chemie International Edition, 2018
- Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathiesAnnals of Clinical and Translational Neurology, 2016
- A practical approach to crosslinkingMolecular Biology Reports, 1993